News | Radiation Therapy | July 05, 2019

Aktina Medical Partners With Elekta for Global Distribution of Interlocking SRS Cones

Cones allow radiation therapy clinics to deliver stereotactic radiosurgery with existing general purpose radiotherapy equipment

Aktina Medical Partners With Elekta for Global Distribution of Interlocking SRS Cones

July 5, 2019 — Aktina Medical announced that Elekta Instrument AB, based in Sweden, will offer and distribute the Aktina line of patented SRS Cones globally for use in cancer treatments and other appropriate radiation therapies.

The use of calibrated cones in stereotactic radiosurgery has grown in recent years, particularly in clinics that do not have access to the most advanced special-purpose radiation treatment equipment. By using the Aktina SRS Cones, such clinics can deliver highly accurate SRS treatments using their existing general-purpose radiation treatment equipment.

Unlike previous solutions, the Aktina SRS Cone system features lead-based interlocking cones with stainless steel sleeves that have carved channels and grooves that match corresponding channels and grooves carved into the applicator. As each cone is inserted into the applicator, they depress (or don’t depress) specific switches, and confirm by their own insertion that they are the proper size cone for the programmed dosage. The control software, which has been integrated with the cones and applicator, compares the installed cone with the programmed plan and confirms they match before proceeding. In this way, automated treatment verification lets technicians benefit from fast, simple equipment setup while ensuring they deliver the correct dosage and treatment specified for the patients.

For more information: www.aktina.com, www.elekta.com

Related Content

Low four-year rates of gastrointestinal (13.6 percent) and urologic issues (7.6 percent) suggest hypofractionated proton therapy as an alternative to traditional radiotherapy to reduce toxicity.

Low four-year rates of gastrointestinal (13.6 percent) and urologic issues (7.6 percent) suggest hypofractionated proton therapy as an alternative to traditional radiotherapy to reduce toxicity.

Feature | Prostate Cancer | October 16, 2019 | By Jeff Zagoudis
Radiation therapy is an important tool in the clinician’s armamentarium for treatment of localized, early-stage prost
Videos | Radiation Oncology | October 11, 2019
Lorraine Drapek, DNP, nurse practitioner, radiation oncology, GI service,...
Patient Treatments With ViewRay's MRIdian Linac Begin in New England
News | Image Guided Radiation Therapy (IGRT) | October 08, 2019
ViewRay Inc. announced today that patient treatments are scheduled to begin in Boston with ViewRay's MRIdian Linac...
ProTom International received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Radiance 330 proton therapy system
News | Proton Therapy | October 07, 2019
ProTom International received 510(k) clearance from the U.S.
Attendees of ASTRO 2019 walked the halls of McCormick Place in Chicago, Ill.

Attendees of ASTRO 2019 walked the halls of McCormick Place in Chicago, Ill.

Feature | ASTRO | October 03, 2019 | By Greg Freiherr
At the American Society for Radiation Oncology’s (ASTRO) 2019 a
Videos | Prostate Cancer | September 30, 2019
Bill Hartsell, M.D., medical director of the Northwestern Medicine Proton Center in Warrenville, Ill., discusses the
eBook on Hypofractionation in the Age of Value-based Care

eBook on Hypofractionation in the Age of Value-based Care

Sponsored Content | Case Study | Radiation Therapy | September 30, 2019
Hypofractionated and ultrahypofractionated radiation therapy — increasing dose per fraction to enable significantly f
AI Accurately Predicts Radiotherapy Side Effects for Head and Neck Cancer Patients
News | Artificial Intelligence | September 26, 2019
For the first time, a sophisticated computer model has been shown to accurately predict two of the most challenging...